AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE1012.754.25 (+0.42 %)
PREV CLOSE ( ) 1008.50
OPEN PRICE ( ) 1010.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 75622
TODAY'S LOW / HIGH ( )1001.10 1023.00
52 WK LOW / HIGH ( )639.85 1038
NSE1013.054 (+0.4 %)
PREV CLOSE( ) 1009.05
OPEN PRICE ( ) 1009.10
BID PRICE (QTY) 1013.05 (1567)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2295907
TODAY'S LOW / HIGH( ) 1001.00 1023.00
52 WK LOW / HIGH ( )639.6 1039
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 26-12 1986
Management Info
K Ragunathan - Chairman N Govindarajan - Managing Director
Registered Office

Address Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone +91-040-66725000

Email info@aurobindo.com

Website www.aurobindo.com

Registrars Details
K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS
31Mar Announcement under Regulation 30 (LOD
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
01Mar Information Under Regulation 30 Of Th
The Board of Directors of Aurobindo Pharma Limited ('the Company') at it..
25Feb Aurobindo Pharma informs about transcr
With reference to its letter dated February 9, 2021 wherein the company..
24Feb Bharti Airtel, NTPC and Gayatri Projec
Bharti Airtel and Qualcomm have entered into collaboration for accelerat..
24Feb Aurobindo Pharma inks pact to invest i
Aurobindo Pharma has entered into binding agreements to invest Rs 5.38 c..
Financials
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit7405.1000000000118727.4
Gross Profit 10122.5 23777
Operating Profit 11387.229437.6
Net Sales 37108.6132664.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Abbott India (BSE)
 15853.10 (2.78%)
M.Cap (Rs. in Cr)33686.73
Themis Medicare (BSE)
 448.00 (19.15%)
M.Cap (Rs. in Cr)411.64
Neuland Laboratories (BSE)
 2682.90 (2.38%)
M.Cap (Rs. in Cr)3442.13
Sanofi India (BSE)
 7759.25 (0.81%)
M.Cap (Rs. in Cr)17870.04
Alkem Laboratories (BSE)
 2908.20 (1.63%)
M.Cap (Rs. in Cr)34771.89
Shareholding Pattern
PROMOTERS 51.94%
NON-INSTITUTION 10.45%
MUTUAL FUNDS/UTI 8.84%
FI/BANKS/INSURANCE 2.15%
GOVERNMENT 0%
FII 0%
ATTENTION INVESTORSKYCIPO
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016

INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075,9768009000, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

Copyright © 2016 NNM Securities.com

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.